28 . 11 .2024
Press release
Galderma’s phase III OLYMPIA 1 data published in JAMA Dermatology demonstrate that nemolizumab improves core signs and symptoms of prurigo nodularis
04 . 11 .2024
Press release
Celebrating 25 years of Sculptra®: new data and recent approval in China cements Galderma’s leadership in regenerative biostimulation
25 . 10 .2024
Press release
Galderma brings together over 650 healthcare professionals from Asia-Pacific to elevate knowledge of future aesthetic trends
24 . 10 .2024
Press release
Galderma delivers record net sales of 3.259 B USD in the first nine months of 2024, demonstrates significant innovation progress, confirms and narrows its full year net sales guidance
21 . 10 .2024
Press release
ASDS 2024: new phase III READY-4 data demonstrate long-term safety and efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™)
17 . 10 .2024
News story
ASDS 2024: Galderma presents data on RelabotulinumtoxinA and Sculptra®
25 . 09 .2024
Press release
EADV 2024 Late breaking news sessions: new Galderma data demonstrating nemolizumab’s long-term efficacy and safety in atopic dermatitis and durability in prurigo nodularis to be shared during three oral presentations
17 . 09 .2024
Press release
Galderma reaffirms its leadership in dermatology with extensive presence at EADV 2024
